ClinicalTrials.gg
CompletedNCT05458856TriptoSwitchUpdated Jul 25, 2025Results posted

Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate

A Phase 3 interventional study of Triptorelin embonate 22.5 mg in Prostate Cancer, sponsored by Ipsen. Completed at 39 sites in 7 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-25.

Sponsored by Ipsen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
147
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing triptorelin in Prostatic Neoplasms — 6 open to participants now, 6 under way, 3 of them phase 3. triptorelin · Prostatic Neoplasms.

Enrollment
10th of 28
147 · median 120
Started
2022
with 1 other
Phase 3
12 of 28
2 open now
Registered
21st of 28
by date
Lead sponsor
9 of 28
Ipsen

Among the 28 studies testing triptorelin in Prostatic Neoplasms, this one is the 10th largest by enrollment, is one of 2 that started in 2022, is one of 12 in phase 3, and was the 21st registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

6 of the 28 studies testing triptorelin in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About triptorelin

triptorelin: first FDA approval 2000 (TRELSTAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing triptorelin in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The aim of the study is to determine if triptorelin formulated for use every 6 months (given twice during the study) is effective and safe for when given by injection under the skin for the treatment of adult males with cancer in the prostate.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is male and must be 18 years of age inclusive, at the time of signing the
  • Participant has or cytologically proven prostate cancer with rising PSA after failed local therapy or disease, or requiring radiotherapy, and be a candidate for long-term (i.e. >1 year) androgen deprivation therapy
  • Participant requires a GnRH analogue treatment for a minimum of 18 months, of which a minimum of 3 months of GnRH analogue treatment has already been provided prior to screening. (Note: participants must receive study intervention on Day 1 in accordance with the treatment schedule of their previously received GnRH analogue therapy).
  • Has serum testosterone levels \<1.735 nmol/L (50 ng/dL) at screening
  • Has (ECOG) performance status score of 0 to 1
  • Has a of >18 months
  • Male participants must agree that, if their partner is at risk of becoming pregnant (although highly unlikely in this study population), they will use an effective method of . The participant must agree to use the contraception during the whole of the study and for 9 months after the last dose of study intervention
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol

Exclusion criteria

Exclusion Criteria :

  • Presence of another neoplastic lesion or
  • hormone-sensitive prostate cancer with high tumour burden
  • Metastatic castration-resistant prostate cancer
  • Any concomitant disorder or resulting therapy that is likely to interfere with participant compliance or with the study in the opinion of the investigator
  • Use of finasteride (Proscar®) or dutasteride (Avodart®/Avolve®) within the past 6 months
  • Planned intermittent scheme of GnRH analogue
  • At the time of screening, planned use of any chemotherapy for prostate cancer during the study
  • Prior hypophysectomy or adrenalectomy
  • Participation in another study with an experimental drug within 3 months before signing or within five half-lives of the drug (whichever was the longer), or any other type of medical research
  • Severe kidney or liver failure (creatinine >2 times the normal range, and alanine aminotransferase >3 times the normal range)
  • Any concomitant disorder or resulting therapy that is likely to interfere with participant's compliance, the subcutaneous administration of the drug or with the study in the opinion of the investigator
  • Previous history of or concomitant use of medicinal products known to prolong the QT interval or with a known risk of torsades de pointes
  • Known to triptorelin or any of its , GnRH, other GnRH agonist/analogues
  • Known active use of recreational drug or alcohol dependence in the opinion of the investigator
  • Inability to give informed consent or to comply fully with the protocol
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
147 participants (actual)

Study arms

  • Experimental
    Triptorelin embonate

    All participants will receive triptorelin embonate 22.5 mg

    Drug: Triptorelin embonate 22.5 mg

Interventions

  • A prolonged release formulation of triptorelin pamoate 22.5 mg 6-month formulation in D, L-lactide-co-glycolide polymers for single subcutaneous injection on Day 1 and Day 169

    Also known as: Decapeptyl

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Maintained Castrate Levels of Serum Testosterone During the Study

    Blood samples were collected for the measurement of serum testosterone concentrations using a validated, specific and sensitive liquid chromatography tandem mass spectrometry method. Maintenance of castration during the study was defined as testosterone \<1.735 nanomoles per liter (nmol/L) (\<50 nanograms/deciliter \[ng/dL\]) at Days 29, 85, 141, 169, 253, 309 and 337.

    Time frame: Up to Day 337

Secondary outcomes

  1. Percentage of Participants Castrated on Days 29, 85, 141, 169, 253, 309 and 337

    Blood samples were collected for the measurement of serum testosterone concentrations using a validated, specific and sensitive liquid chromatography tandem mass spectrometry method. Castration was defined as testosterone \<1.735 nmol/L (\<50 ng/dL).

    Time frame: Days 29, 85, 141, 169, 253, 309 and 337

  2. Percentage of Participants With a Serum Testosterone Level <0.694 Nmol/L (<20 ng/dL) During the Study

    Blood samples were collected for the measurement of serum testosterone concentrations using a validated, specific and sensitive liquid chromatography tandem mass spectrometry method.

    Time frame: Up to Day 337

  3. Percentage of Participants With a Serum Testosterone Level <0.694 Nmol/L (<20 ng/dL) on Days 29, 85, 141, 169, 253, 309 and 337

    Blood samples were collected for the measurement of serum testosterone concentrations using a validated, specific and sensitive liquid chromatography tandem mass spectrometry method.

    Time frame: Days 29, 85, 141, 169, 253, 309 and 337

  4. Percentage of Participants Castrated on Days 3 and 7 After Each Injection Administered on Days 1 and 169

    Blood samples were collected for the measurement of serum testosterone concentrations using a validated, specific and sensitive liquid chromatography tandem mass spectrometry method. Castration was defined as testosterone \<1.735 nmol/L (\<50 ng/dL).

    Time frame: On Days 3, 7, 171, and 175

  5. Percent Change From Baseline in Prostate Specific Antigen (PSA) at Days 169 and 337

    Blood samples were collected for the measurement of plasma PSA concentrations. Percent change in PSA was defined as the absolute value of the difference between the PSA values at Days 169 and 337 and the baseline value divided by the baseline value. The baseline value was the last sample prior to the first injection.

    Time frame: Baseline (prior to injection on Day 1), Days 169 and 337

  6. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and TEAEs of Local Intolerance

    An adverse event (AE) was any untoward medical occurrence in clinical study participant, temporally associated with use of study treatment, whether or not considered related to study treatment. TEAEs were AEs that started or worsened on or after the first study treatment administration and within 168 days after the last dose of study treatment, or up to Day 337, whichever was later. Local tolerance was assessed 2 hours after each injection by examination of injection site for signs such as but not limited to tenderness, redness, bruising, erythema, swelling, rash, pain, itching, induration, hematoma, ulceration or necrosis.

    Time frame: From first dose of study treatment (Day 1) up to end of study visit (Day 337)

07

Results

Posted Jul 23, 2025

Participant flow

This Phase III, multicenter, open-label, single arm study was conducted at 26 investigational sites in 6 countries from 30-Aug-2022 to 08-Jul-2024 in participants with locally advanced and/or metastatic prostate cancer previously treated and castrated with a gonadotropin-releasing hormone (GnRH) analogue.

Participant flow — Overall Study
MilestoneTriptorelin Embonate 22.5 mg
Started147
Received treatment145
Completed134
Not completed13
Withdrew: Withdrawal by subject5
Withdrew: Death4
Withdrew: Protocol deviation3
Withdrew: Physician decision1

Outcome measures

PrimaryPercentage of Participants Who Maintained Castrate Levels of Serum Testosterone During the Study

Blood samples were collected for the measurement of serum testosterone concentrations using a validated, specific and sensitive liquid chromatography tandem mass spectrometry method. Maintenance of castration during the study was defined as testosterone \<1.735 nanomoles per liter (nmol/L) (\<50 nanograms/deciliter \[ng/dL\]) at Days 29, 85, 141, 169, 253, 309 and 337.

Time frame:
Up to Day 337
Reported as:
Number · percentage of participants
Percentage of Participants Who Maintained Castrate Levels of Serum Testosterone During the Study
percentage of participantsTriptorelin Embonate 22.5 mg
Percentage of Participants Who Maintained Castrate Levels of Serum Testosterone During the Study95.0 (89.4 to 98.1)
SecondaryPercentage of Participants Castrated on Days 29, 85, 141, 169, 253, 309 and 337

Blood samples were collected for the measurement of serum testosterone concentrations using a validated, specific and sensitive liquid chromatography tandem mass spectrometry method. Castration was defined as testosterone \<1.735 nmol/L (\<50 ng/dL).

Time frame:
Days 29, 85, 141, 169, 253, 309 and 337
Reported as:
Number · percentage of participants
Percentage of Participants Castrated on Days 29, 85, 141, 169, 253, 309 and 337
percentage of participantsTriptorelin Embonate 22.5 mg
Day 29100.0 (97.0 to 100.0)
Day 85100.0 (97.0 to 100.0)
Day 14198.3 (94.1 to 99.8)
Day 16997.5 (92.9 to 99.5)
Day 253100.0 (97.0 to 100.0)
Day 30999.2 (95.4 to 100.0)
Day 33799.2 (95.4 to 100.0)
SecondaryPercentage of Participants With a Serum Testosterone Level <0.694 Nmol/L (<20 ng/dL) During the Study

Blood samples were collected for the measurement of serum testosterone concentrations using a validated, specific and sensitive liquid chromatography tandem mass spectrometry method.

Time frame:
Up to Day 337
Reported as:
Number · percentage of participants
Percentage of Participants With a Serum Testosterone Level <0.694 Nmol/L (<20 ng/dL) During the Study
percentage of participantsTriptorelin Embonate 22.5 mg
Percentage of Participants With a Serum Testosterone Level <0.694 Nmol/L (<20 ng/dL) During the Study83.3 (75.4 to 89.5)
SecondaryPercentage of Participants With a Serum Testosterone Level <0.694 Nmol/L (<20 ng/dL) on Days 29, 85, 141, 169, 253, 309 and 337

Blood samples were collected for the measurement of serum testosterone concentrations using a validated, specific and sensitive liquid chromatography tandem mass spectrometry method.

Time frame:
Days 29, 85, 141, 169, 253, 309 and 337
Reported as:
Number · percentage of participants
Percentage of Participants With a Serum Testosterone Level <0.694 Nmol/L (<20 ng/dL) on Days 29, 85, 141, 169, 253, 309 and 337
percentage of participantsTriptorelin Embonate 22.5 mg
Day 2992.5 (86.2 to 96.5)
Day 8592.5 (86.2 to 96.5)
Day 14192.5 (86.2 to 96.5)
Day 16994.2 (88.4 to 97.6)
Day 25395.8 (90.5 to 98.6)
Day 30995.8 (90.5 to 98.6)
Day 33798.3 (94.1 to 99.8)
SecondaryPercentage of Participants Castrated on Days 3 and 7 After Each Injection Administered on Days 1 and 169

Blood samples were collected for the measurement of serum testosterone concentrations using a validated, specific and sensitive liquid chromatography tandem mass spectrometry method. Castration was defined as testosterone \<1.735 nmol/L (\<50 ng/dL).

Time frame:
On Days 3, 7, 171, and 175
Reported as:
Number · percentage of participants
Percentage of Participants Castrated on Days 3 and 7 After Each Injection Administered on Days 1 and 169
percentage of participantsTriptorelin Embonate 22.5 mg
Day 392.5 (86.2 to 96.5)
Day 798.3 (94.1 to 99.8)
Day 17195.0 (89.4 to 98.1)
Day 17595.8 (90.5 to 98.6)
SecondaryPercent Change From Baseline in Prostate Specific Antigen (PSA) at Days 169 and 337

Blood samples were collected for the measurement of plasma PSA concentrations. Percent change in PSA was defined as the absolute value of the difference between the PSA values at Days 169 and 337 and the baseline value divided by the baseline value. The baseline value was the last sample prior to the first injection.

Time frame:
Baseline (prior to injection on Day 1), Days 169 and 337
Reported as:
Median · percent change
Percent Change From Baseline in Prostate Specific Antigen (PSA) at Days 169 and 337
percent changeTriptorelin Embonate 22.5 mg
Day 1690.00 (-35.60 to 0.00)
Day 3370.00 (-46.90 to 14.30)
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and TEAEs of Local Intolerance

An adverse event (AE) was any untoward medical occurrence in clinical study participant, temporally associated with use of study treatment, whether or not considered related to study treatment. TEAEs were AEs that started or worsened on or after the first study treatment administration and within 168 days after the last dose of study treatment, or up to Day 337, whichever was later. Local tolerance was assessed 2 hours after each injection by examination of injection site for signs such as but not limited to tenderness, redness, bruising, erythema, swelling, rash, pain, itching, induration, hematoma, ulceration or necrosis.

Time frame:
From first dose of study treatment (Day 1) up to end of study visit (Day 337)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and TEAEs of Local Intolerance
ParticipantsTriptorelin Embonate 22.5 mg
TEAEs88
TEAEs of Local Intolerance19

Adverse events

Collected over Serious AEs, non-serious AEs and all-cause mortality (deaths) were collected from screening (Day -28) up to end of study visit (Day 337), up to maximum of 365 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Triptorelin Embonate 22.5 mg4/145 (2.8%)26/145 (17.9%)38/145 (26.2%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventTriptorelin Embonate 22.5 mg
COVID-19Infections and infestations4/145
Disease progressionGeneral disorders2/145
Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/145
Anal abscessInfections and infestations1/145
AppendicitisInfections and infestations1/145
Lyme diseaseInfections and infestations1/145
PneumoniaInfections and infestations1/145
Foot fractureInjury, poisoning and procedural complications1/145
Head injuryInjury, poisoning and procedural complications1/145
Peroneal nerve injuryInjury, poisoning and procedural complications1/145
Most frequent other events
Most frequent other events
EventTriptorelin Embonate 22.5 mg
Hot flushVascular disorders17/145
HypertensionVascular disorders14/145
FallInjury, poisoning and procedural complications9/145
FatigueGeneral disorders8/145

Baseline characteristics

The enrolled set included all participants who were enrolled to study treatment.

Age, Continuous
Age, Continuous(years)Triptorelin Embonate 22.5 mg
Mean71.8 ± 8.43
Sex: Female, Male
Sex: Female, Male(Participants)Triptorelin Embonate 22.5 mg
Female0
Male147
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Triptorelin Embonate 22.5 mg
Hispanic or Latino4
Not Hispanic or Latino104
Unknown or Not Reported39
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Triptorelin Embonate 22.5 mg
White109
Other2
Not Reported36
08

Study locations

39 sites
  • Cliniques Universitaires Saint-Luc
    Brussels, Belgium
  • UZ Antwerpen
    Edegem, Belgium
  • AZGroeninge
    Kortrijk, 8500, Belgium
  • CHU de Liège - Domaine Universitaire du Sart Tilman - Urologie
    Liège, Belgium
  • Fakultni nemocnice u sv. Anny v Brne
    Brno, Czechia
  • Fakultni nemocnice Olomouc
    Olomouc, Czechia
  • Vseobecna Fakultni Nemocnice V Praze
    Prague, Czechia
  • Centre Hospitalier Universitaire D'Angers - Urologie
    Angers, 49933, France
  • CHU Brest-Hopital Morvan Institut de Cancerologie et d'Hemat
    Brest, 29200, France
  • Clinique Pasteur-Lanroze - Oncology
    Brest, 29229, France
  • Polyclinique de Blois - Service oncologie
    La Chaussée-Saint-Victor, 41260, France
  • Hopital Privé Métropole Lille - Polyclinique Du Bois
    Lille, 59000, France
  • CHU Hopital Edouard Herriot
    Lyon, 69437, France
  • L'Institut Mutualiste Montsouris
    Paris, 75014, France
  • Hopital Bichat
    Paris, 75018, France
  • Centre hospitalier Lyon Sud
    Pierre-Bénite, 69495, France
  • Hopital Foch - Urologie et Transplantation Ré
    Suresnes, 92151, France
  • Saint Jean Languedoc and La Croix du Sud Hospital
    Toulouse, 31400, France
  • Universitätsklinikum Carl Gustav Carus
    Dresden, 01307, Germany
  • University Hospital Jena KöR
    Jena, Germany
  • Universitaetsklinikum Muenster
    Münster, 48149, Germany
  • Studienpraxis Urologie
    Nürtingen, 72622, Germany
  • Universität Tuebingen - Urology
    Tübingen, Germany
  • Hospital of Lithuanian University of Health Sciences Kaunas
    Kaunas, Lithuania
  • Klaipeda University Hospital
    Klaipėda, LT92288, Lithuania
  • National Cancer Institute
    Vilnius, LT-08660, Lithuania
  • Vilniaus Universiteto ligonines Santariskiu Klinikos
    Vilnius, Lithuania
  • The Netherlands Cancer Institute - Oncology
    Amsterdam, Netherlands
  • Catharina Ziekenhuis - Urology
    Eindhoven, 5623 EJ, Netherlands
  • CWZ
    Nijmegen, 6532 SZ, Netherlands
  • Haga Ziekenhuis
    The Hague, Netherlands
  • Hospital Universitario Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital de La Santa Creu i Sant Pau - Oncología Médica
    Barcelona, 08041, Spain
  • H. de Basurto - Urología
    Bilbao, 48013, Spain
  • POLUSA - Policlínico Lucense - Oncología
    Lugo, 27004, Spain
  • Hospital Universitario 12 de Octubre- Urology
    Madrid, 28041, Spain
  • Hospital Universitario Central de Asturias (HUCA)
    Oviedo, 33011, Spain
  • Hospital Universitario Virgen del Rocio- Urología Pediátrica
    Seville, 41013, Spain
  • Hospital Universitari i Politecnic La Fe
    Valencia, 46026, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants. Any requests should be submitted to www.vivli.org for assessment by an independent scientific review board.

Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and EU or after the primary manuscript describing the results has been accepted for publication, whichever is later.

Access criteria: Access Criteria: Further details on Ipsen's sharing criteria, eligible studies and process for sharing are available here (https://vivli.org/members/ourmembers/).

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Jul 2024, 22 months.

Results were first posted in Jul 2025, 1 year after primary completion.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 22 months is below that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2022
First posted
Jul 14, 2022
StartActual
Aug 30, 2022
Primary completionActual
Jul 8, 2024
CompletionActual
Jul 8, 2024
Results first posted
Jul 23, 2025
Last update
Jul 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05458856
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Jul 14, 2022
Start date
Aug 30, 2022
Primary completion
Jul 8, 2024
Completion
Jul 8, 2024
Results posted
Jul 23, 2025
Last update
Jul 25, 2025

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Triptorelin

Start the discussion